News about Global Pharma

Syntegon Posts Record Year in 2025 and Aims for Further Growth

Syntegon reports a record 2025 with revenue up 10 percent to €1.75 billion and pharma sales surging 22 percent, alongside strong EBITDA and cash flow growth, reinforcing its position as a key lifecycle partner for pharma, biotech and food industries.

Global Pharma | 21/04/2026 | By News Bureau |  387

Interna Therapeutics and Daiichi Sankyo Partner to Advance MNM-Based Targeted Delivery Technology

Interna Therapeutics and Daiichi Sankyo collaborate to advance MNM-based targeted delivery technologies, aiming to enhance intracellular delivery, boost therapeutic activity, and improve performance across key drug development programs.

Global Pharma | 17/04/2026 | By News Bureau |  194

Mabwell Strengthens China Pipeline with NMPA Acceptance for Denosumab

Mabwell announces NMPA acceptance of its sBLA for MAIWEIJIAN (denosumab), China’s first approved 120mg denosumab biosimilar, used to treat giant cell tumor of bone in adults and adolescents.

Global Pharma | 17/04/2026 | By News Bureau |  260

Kazia Expands Oncology Platform with First-in-Class SETDB1 Inhibitor

Kazia Therapeutics expands its oncology platform with a first-in-class SETDB1 inhibitor, leveraging an AI-driven epigenetic drug discovery engine for faster and scalable candidate development.

Global Pharma | 15/04/2026 | By News Bureau |  252

Ifinatamab Deruxtecan Gets US Priority Review for Small Cell Lung Cancer

Ifinatamab deruxtecan receives US Priority Review for Small Cell Lung Cancer, supported by Phase 2 data, with potential as a first-in-class B7-H3 targeted Antibody Drug Conjugate.

Global Pharma | 13/04/2026 | By News Bureau |  354

Daiichi Sankyo Partners with Imagene AI for Biomarker Discovery

Through collaboration, Imagene AI and Daiichi Sankyo will apply multimodal AI to improve biomarker discovery with the goals of advancing precision oncology and enhancing clinical trial success rates.

Global Pharma | 11/04/2026 | By News Bureau |  338

Inventia Healthcare Launches Generic Dapagliflozin in US After FDA Approval

Inventia Healthcare has secured FDA approval for dapagliflozin tablets and begun Day-One commercialisation, expanding access to affordable diabetes and heart failure treatment in the US.

Global Pharma | 09/04/2026 | By News Bureau |  464

Nuvalent Submits NDA to FDA for Neladalkib in Advanced ALK-Positive Lung Cancer

The investigational ALK inhibitor, backed by Phase I/II trial data, targets treatment-resistant non-small cell lung cancer and has received breakthrough and orphan drug designations.

Global Pharma | 08/04/2026 | By News Bureau |  204

Denali Regains Full Rights to DNL593 After Takeda Ends Collaboration

The biotech firm will independently advance its investigational therapy for frontotemporal dementia, with Phase I/II trial results expected by 2026.

Global Pharma | 08/04/2026 | By News Bureau |  179

Neurocrine Biosciences to Acquire Soleno Therapeutics in USD 2.9 Billion Deal

The acquisition brings first-in-class Prader-Willi syndrome therapy VYKAT XR into Neurocrine’s portfolio, strengthening its position in endocrinology and rare diseases.

Global Pharma | 07/04/2026 | By News Bureau |  160